Crossmark

The new era of AML therapy: current standards and emerging targets

Published Online: 2026-04-17

Published Print: 2026-07

Authors

Hosono, Naoko https://orcid.org/0000-0002-6336-3250
Funding

Funding for this research was provided by:

University of Fukui
License Information

Text and Data Mining valid from 2026-04-17

Version of Record valid from 2026-04-17
More Information

Article History

Received: 18 February 2026

Accepted: 6 April 2026

First Online: 17 April 2026

Declarations

:

: Lecture fees: AbbVie GK, Nippon Shinyaku Co., Ltd., Daiichi Sankyo Co., Ltd., and Astellas Pharma Inc.

Document is current